Company Information
- CEO
- Khalid Islam
- Investor Relations
- Harry Welten
Arpida is a biopharmaceutical company specialising in research into and development of new products for treating serious bacterial infections. The company has a fully integrated platform for discovering and developing medications for fighting bacteria that are becoming increasingly resistant to antibiotics.
Trading Information
- Sector
- Health Care - 4500
- Regulatory Standard
- International Reporting Standard
- Security Number
- 2121806
- ISIN
- CH0021218067
- Symbol
- ARPN
- Index member
- SPI, SPIEX
Intermediaries
- Listing Agent
- Deutsche Bank AG London Branch
- Lead Bank
- Deutsche Bank AG Zurich Branch
- Auditor
- PricewaterhouseCoopers AG
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 04.05.2005 |
| Class of Share | Action nominative |
| Nominal Value | 0.20 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 16371959 |
| Allocation Details | |
|---|---|
| Primary Shares | 5400000 |
| Secondary Shares | n/a |
| Primary Greenshoe | 810000 |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | no |
| Ex-date | n/a |
| Executed number of shares | n/a |
| First Trading Day Details | |
|---|---|
| First Trading | 04.05.2005 |
| Price Range | 18.00 - 22.00 CHF |
| Issue Price | 18.00 CHF |
| First Open | 16.75 CHF |
| First Close | 13.30 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | 97.2 CHF |
| Market Capitalisation in Mio. (based on first closing price) | 218 CHF |
Financial Statement
| Number of Employees | 72 |
| Net Revenues in Mio. | 0.06 CHF |
| Net Gain in Mio. | n/a |